Overview
Thymosin Alpha-1 is classified as a immune peptide peptide. Immune support, antiviral, recovery.
Enhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
Also known as: Tα1, Zadaxin
Category
Immune Peptide
Half-Life
2h
Route
SubQ
FDA Status
Not Approved
How Does Thymosin Alpha-1 Work?
Enhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
At the molecular level, Thymosin Alpha-1 operates through pathways characteristic of the Immune Peptide class, interacting with target receptors and downstream signaling cascades to produce its observed effects.
Published Research
The following studies are indexed from PubMed and peer-reviewed journals:
[1]Thymosin Alpha-1 in immune-compromised patients
Garaci et al.: Review of Tα1 use in immune-compromised patients showing enhanced T-cell function, improved dendritic cell activity, and cytokine modulation.
Evidence: moderate strong[2]Thymosin Alpha-1 safety/efficacy: review of 30+ clinical trials
King & Tuthill: Comprehensive review of 30+ clinical trials involving 11,000+ subjects confirming Tα1's consistent safety and efficacy across hepatitis B/C, cancer, and infections.
Evidence: strong[3]Thymosin Alpha-1 as adjunct in hepatitis B treatment
Mutchnick et al. (Hepatology): Randomized trial showing Tα1 combined with interferon significantly improves virologic response in chronic hepatitis B vs. interferon alone.
Evidence: strong[4]Thymosin Alpha-1 in sepsis and critical care
Evidence review of Tα1 in septic shock, ARDS, and peritonitis showing improved survival and immune recovery in critically ill patients.
Evidence: moderate strong[5]Thymosin Alpha-1 as cancer immunotherapy adjuvant
Garaci et al. (Ann. N.Y. Acad. Sci.): Review of Tα1 as cancer immunotherapy adjunct, showing enhanced chemotherapy tolerance and improved immune recovery in multiple tumor types.
Evidence: moderate[6]Mechanism and clinical application of thymosin in the treatment of lung cancer.
A study published in Frontiers in immunology investigating the effects and mechanisms.
Evidence: moderate[7]Serum thymosin alpha 1 levels in normal and pathological conditions.
A study published in Expert opinion on biological therapy investigating the effects and mechanisms.
Evidence: preclinical[8]Thymosin α-1 in cancer therapy: Immunoregulation and potential applications.
A study published in International immunopharmacology investigating the effects and mechanisms.
Evidence: preclinical[9]Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy.
A study published in Cell reports. Medicine investigating the effects and mechanisms.
Evidence: preclinical[10]Thymosin alpha 1 and HIV-1: recent advances and future perspectives.
A study published in Future microbiology investigating the effects and mechanisms.
Evidence: preclinical[11]Thymosin alpha 1: past clinical experience and future promise.
A study published in Annals of the New York Academy of Sciences investigating the effects and mechanisms.
Evidence: moderate[12]Clinical applications of thymosin alpha-1.
A study published in Cancer investigation investigating the effects and mechanisms.
Evidence: moderate[13]Thymosin alpha-1 treatment in chronic hepatitis B.
A study published in Expert opinion on biological therapy investigating the effects and mechanisms.
Evidence: preclinical[14]A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection.
A study published in The Journal of infectious diseases investigating the effects and mechanisms.
Evidence: moderate[15]Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity.
A study published in Scientific reports investigating the effects and mechanisms.
Evidence: preclinical[16]Structures of Thymosin Proteins.
A study published in Vitamins and hormones investigating the effects and mechanisms.
Evidence: preclinical[17]Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer.
A study published in International immunopharmacology investigating the effects and mechanisms.
Evidence: preclinical[18]Thymosin alpha 1 for treatment of hepatitis C virus: promise and proof.
A study published in Annals of the New York Academy of Sciences investigating the effects and mechanisms.
Evidence: preclinical[19]Unmet needs in cystic fibrosis.
A study published in Expert opinion on biological therapy investigating the effects and mechanisms.
Evidence: preclinical[20]Thymic endocrinology.
A study published in International journal of immunopharmacology investigating the effects and mechanisms.
Evidence: preclinicalSafety Profile
Approved in 35+ countries for hep B/C. One of the most extensively studied peptides. Not FDA-approved in US.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~5% of users | mild |
| Mild flu-like symptoms (immune activation) | ~5% of users | mild |
Sourcing Thymosin Alpha-1 for Research
If you're looking to source Thymosin Alpha-1 for laboratory research, our vendor directory compares pricing, purity testing, and COA verification from independently vetted suppliers.
* Research vendor — verify your regional regulations before purchase.
Full Research Profile
Thymosin Alpha-1 — dosing, interactions, timelines & more
Comprehensive compound profile with sourcing information, stacking synergies, and outcome timelines.